Accurate prediction of adverse effects improves significantly with knowing a drug’s interactions with key enzymes.
bRo5: Building a platform for high-throughput development of PROTACs and molecular glues
IN PARTNERSHIP WITH THE UNIVERSITY OF TORINO AND MCGILL UNIVERSITY Expanding bRo5 chemical space and accurately modeling ternary complex stability are key In collaboration with the University of Turin (Italy) and McGill University, we are constructing an automated, end-to-end in silico…
Pediatric Acute Myeloid Leukemia: Accelerating the discovery of low-toxicity drug candidates
IN PARTNERSHIP WITH THE US DEPARTMENT OF DEFENSE, THE MINISTRY OF INNOVATION OF QUEBEC, AND MCGILL UNIVERSITY Targeting fusion oncoproteins is key to advancing pediatric AML treatment. Currently, AML therapies exhibit high toxicity and limited efficacy, resulting in a 5-year survival…